These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 37839365)

  • 1. The effect of disease modifying therapies on fatigue in multiple sclerosis.
    Cruz Rivera S; Aiyegbusi OL; Piani Meier D; Dunne A; Harlow DE; Henke C; Kamudoni P; Calvert MJ
    Mult Scler Relat Disord; 2023 Nov; 79():105065. PubMed ID: 37839365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incomplete reporting of patient-reported outcomes in multiple sclerosis: A meta-epidemiological study of randomized controlled trials.
    Khan T; Khalid M; Dunford B; Nguyen T; Wise A; Heigle B; Shepard S; Kee M; Hillman C; Ottwell R; Hartwell M; Vassar M
    Mult Scler Relat Disord; 2022 Jul; 63():103819. PubMed ID: 35487036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Underreporting of patient-reported outcomes in cystic fibrosis randomized controlled trials using CONSORT-PRO and RoB 2.0.
    Moore T; Nees D; Hightower B; Brock L; Kee M; Wise A; Heigle B; Ottwell R; Hartwell M; Vassar M
    Respir Med Res; 2023 Jun; 83():100962. PubMed ID: 36563550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals.
    Turner L; Shamseer L; Altman DG; Weeks L; Peters J; Kober T; Dias S; Schulz KF; Plint AC; Moher D
    Cochrane Database Syst Rev; 2012 Nov; 11(11):MR000030. PubMed ID: 23152285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A snapshot on patient-reported outcome measures of people with multiple sclerosis on first-line therapies in a real world setting.
    Lanzillo R; Sparaco M; Lavorgna L; Carmisciano L; Signoriello E; Signori A; Costabile T; Maniscalco GT; Saccà F; Cepparulo S; Russo CV; Bisecco A; Frattaruolo N; Strianese A; Lus G; Brescia Morra V; Bonavita S
    Neurol Sci; 2020 Nov; 41(11):3235-3241. PubMed ID: 32388646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating the underreporting of patient-reported outcomes in carpal tunnel syndrome randomized controlled trials.
    Ladd C; Jacobsen SM; Snider K; Bacani R; Hillman C; Shepard S; Heigle B; Ottwell R; Hartwell M; Vassar M
    J Osteopath Med; 2023 Jun; 123(6):301-308. PubMed ID: 36840430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sickle Cell Disease and Quality of Life: An Evaluation of Reporting of Patient-Reported Outcomes in Randomized Controlled Trials.
    Renner A; Love M; Garrett E; Douglas A; Kee M; Heigle B; Wise A; Ottwell R; Hartwell M; Vassar M
    Hemoglobin; 2022 Sep; 46(5):265-268. PubMed ID: 36268837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exercise therapy for fatigue in multiple sclerosis.
    Heine M; van de Port I; Rietberg MB; van Wegen EE; Kwakkel G
    Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD009956. PubMed ID: 26358158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical trial evidence of quality-of-life effects of disease-modifying therapies for multiple sclerosis: a systematic analysis.
    Hirt J; Dembowska K; Woelfle T; Axfors C; Granziera C; Kuhle J; Kappos L; Hemkens LG; Janiaud P
    J Neurol; 2024 Jun; 271(6):3131-3141. PubMed ID: 38625399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy for people with clinically isolated syndrome or relapsing-remitting multiple sclerosis: treatment response by demographic, clinical, and biomarker subgroups (PROMISE)-a systematic review protocol.
    Lehnert T; Röver C; Köpke S; Rio J; Chard D; Fittipaldo AV; Friede T; Heesen C; Rahn AC
    Syst Rev; 2022 Jul; 11(1):134. PubMed ID: 35778721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amantadine for fatigue in multiple sclerosis.
    Pucci E; Branãs P; D'Amico R; Giuliani G; Solari A; Taus C
    Cochrane Database Syst Rev; 2007 Jan; 2007(1):CD002818. PubMed ID: 17253480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. As time goes by: Treatment challenges in elderly people with multiple sclerosis.
    Gelibter S; Saraceno L; Pirro F; Susani EL; Protti A
    J Neuroimmunol; 2024 Jun; 391():578368. PubMed ID: 38761652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab for people with multiple sclerosis.
    Filippini G; Kruja J; Del Giovane C
    Cochrane Database Syst Rev; 2021 Nov; 11(11):CD013874. PubMed ID: 34748215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implementing Shared Decision-Making for Multiple Sclerosis: The MS-SUPPORT Tool.
    Col NF; Solomon AJ; Alvarez E; Pbert L; Ionete C; BerriosMorales I; Chester J; Kutz C; Iwuchukwu C; Livingston T; Springmann V; Col HV; Ngo LH
    Mult Scler Relat Disord; 2023 Dec; 80():105092. PubMed ID: 37931489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Information provision for people with multiple sclerosis.
    Köpke S; Solari A; Rahn A; Khan F; Heesen C; Giordano A
    Cochrane Database Syst Rev; 2018 Oct; 10(10):CD008757. PubMed ID: 30317542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. WITHDRAWN: Interventions for fatigue and weight loss in adults with advanced progressive illness.
    Payne C; Wiffen PJ; Martin S
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD008427. PubMed ID: 28387447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interventions for fatigue and weight loss in adults with advanced progressive illness.
    Payne C; Wiffen PJ; Martin S
    Cochrane Database Syst Rev; 2012 Jan; 1():CD008427. PubMed ID: 22258985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation.
    Melendez-Torres GJ; Auguste P; Armoiry X; Maheswaran H; Court R; Madan J; Kan A; Lin S; Counsell C; Patterson J; Rodrigues J; Ciccarelli O; Fraser H; Clarke A
    Health Technol Assess; 2017 Sep; 21(52):1-352. PubMed ID: 28914229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.